NIKKEI 225
38,663.77 +427.70 (+1.12%) HANG SENG
18,595.88 +17.58 (+0.09%) CRUDE OIL
78.68 +0.20 (+0.25%) GOLD FUTURES
2,331.50 +0.30 (+0.01%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,828.61 -229.55 (-0.45%)
MediWound Ltd. (MDWD)
- GlobeNewswire
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase III study YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx® Phase II studies will be
- Zacks
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks
Wall Street Analysts See a 76.89% Upside in MediWound (MDWD): Can the Stock Really Move This High?
The mean of analysts' price targets for MediWound (MDWD) points to a 76.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
